SCHEMBL6767927

SCHEMBL6767927

FC(F)(F)c1nnc(-c2ccc3ncnc(Cl)c3c2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 8/20 0.45
NOTUM Q6P988 3/20 0.38
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
MAP4K4 O95819 4/20 0.36
HTT P42858 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
CYP2C19 P33261 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
USP2 O75604 1/20 0.35
CYP2D6 P10635 1/20 0.35
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764092 0.80 GSK3B (0.43) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL6763937 0.74 HDAC6 (0.59) HDAC6PIM3
SCHEMBL22116888 0.72 NPC1 (0.59) HDAC6NOTUMALDH1A1CYP1A2TSHR
SCHEMBL30203808 0.72 HDAC6 (0.51) HDAC6NOTUMCYP1A2TSHRTP53
SCHEMBL686704 0.70 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DHTT
SCHEMBL22116882 0.70 NPC1 (0.59) HDAC6NOTUMALDH1A1TSHRTP53
SCHEMBL30203745 0.70 NPC1 (0.63) HDAC6NOTUMALDH1A1TSHRTP53
SCHEMBL3338539 0.69 MAP4K4 (0.66) PDE4APDE4BPDE4CPDE4DMAP4K4
SCHEMBL6767023 0.69 LRRK2 (0.40) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL19321936 0.68 HDAC6 (0.55) HDAC6NOTUMHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828320-B2 Enzyme inhibitors; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-12-07 US disclosed
US-20020147214-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 US disclosed
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 US disclosed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 EP disclosed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147214-A1 Heterocyclic compounds BRAF, ABL1, CSK HDAC6 707/4885NOTUM 2563/4885PDE4A 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.